Visceral fat is fat stored deep in the abdomen, around the internal organs. It is different from subcutaneous fat, which sits just under the skin.

The difference is not cosmetic. Visceral fat is active tissue. It releases inflammatory signaling molecules. Its position also gives it direct access to the liver, which subcutaneous fat does not have.

Research consistently links visceral fat to insulin resistance, high blood lipids, high blood pressure and cardiovascular risk. These links hold even after adjusting for total body weight (Fox et al., 2007).

This is why two people with the same BMI can carry very different risk. It also explains why visceral fat is often present in people who do not look overweight.

Visceral fat sits in several places inside the abdomen.

Omental fat hangs in a fold of tissue draped over the intestines. It is usually the largest store.

Mesenteric fat sits in the membrane that anchors the intestines to the abdominal wall.

Retroperitoneal fat lies behind the abdominal lining, around the kidneys.

Perivascular and epicardial fat surround major blood vessels and the heart.

Fat inside the organs themselves is called ectopic fat. This includes fat in the liver, pancreas and muscle. Liver fat tends to track closely with visceral fat, because the same things drive both. How the body stores and burns fuel explains the storage hierarchy.

What links the visceral stores is where their blood drains. Omental and mesenteric fat drain into the portal vein. That vein carries their output straight to the liver before it reaches the rest of the body. Subcutaneous fat drains into general circulation instead. This difference is the basis of what researchers call the portal theory (Item & Konrad, 2012).

Location. Visceral fat surrounds the organs. Subcutaneous fat sits between skin and muscle.

Drainage. Visceral fat drains to the liver through the portal vein. Subcutaneous fat drains into general circulation.

Activity. Visceral fat cells release fatty acids more readily. Subcutaneous fat works more as stable storage.

Inflammation. Visceral fat produces more inflammatory signals, including IL-6 and TNF-alpha. Subcutaneous fat produces more adiponectin, which is linked to better insulin sensitivity.

Measurement. Measuring visceral fat precisely needs imaging. Waist circumference and waist-to-height ratio work as practical stand-ins. Subcutaneous fat can be measured with skinfold calipers.

Response to change. Research suggests visceral fat often responds faster than subcutaneous fat to sustained diet and activity change. That is one of the more encouraging findings in this area.

Three mechanisms explain most of the risk.

Fatty acids go straight to the liver. Omental and mesenteric fat drain into the portal vein. The fatty acids they release arrive at the liver concentrated. Research associates this with impaired insulin signaling in the liver and higher glucose output.

Inflammatory signaling. Visceral fat in metabolic dysfunction holds more immune cells. It releases inflammatory signals into portal blood. The result is chronic low-grade inflammation, which overlaps with the oxidative stress picture.

Fat ends up where it should not be. When storage capacity runs out, fat collects in the liver, pancreas and muscle. This ectopic fat is more closely linked to insulin resistance than total fat mass is (Neeland et al., 2019).

A note on cause and effect. Whether visceral fat causes metabolic problems or mostly marks them is still debated. The relationship probably runs both ways. What is well established is that it is a reliable indicator of risk.

Fructose matters here because of where it is processed. Glucose is taken up throughout the body. Most fructose is processed in the liver. That is the organ sitting at the receiving end of visceral fat’s blood supply.

The clearest human evidence comes from a controlled trial. Participants drank either fructose-sweetened or glucose-sweetened beverages for ten weeks. Both provided 25% of daily energy needs.

Both groups gained similar total weight. Only the fructose group showed a significant rise in visceral fat. That group also showed more fat production in the liver and reduced insulin sensitivity (Stanhope et al., 2009).

The difference was not calories. It was the route those calories took.

The mechanism runs through fructokinase (KHK). This enzyme processes fructose without the brake that regulates glucose. Fructose has no such brake. ATP falls, uric acid is produced, and carbon is directed into making fat. The full fructose metabolism pathway sets out every step.

There is one further point. The polyol pathway turns glucose into fructose internally during high blood glucose, stress and dehydration. So fructose exposure is not set by diet alone.

Visceral fat cannot be seen or pinched. The usual feedback signals are unreliable. Scale weight is a particularly poor guide.

Research suggests visceral fat often responds before total weight does. The scale can sit still while real change is happening, which is one reason a weight loss plateau can be misleading.

Waist circumference. The most practical measure. Take it midway between the lowest rib and the top of the hip bone. Because visceral fat sits inside the abdomen, a smaller waist without a lower scale weight points to visceral fat loss specifically.

Waist-to-height ratio. Below 0.5 is a commonly cited threshold. It adjusts for body size in a way waist measurement alone does not.

How clothes fit at the waistband. Change concentrated at the waist, with limbs unchanged, suggests central fat loss rather than general loss.

Blood markers. Fasting triglycerides, fasting insulin and liver enzymes often improve alongside visceral fat loss. They frequently move before anything is visible.

⚠️ Important: These signs are consistent with visceral fat loss. They are not diagnostic. Precise measurement needs imaging. If a blood marker changes unexpectedly, discuss it with a healthcare provider rather than drawing your own conclusion.

The strongest evidence sits with unglamorous basics. Cut added sugar, especially in liquid form. Managing sugar cravings is usually the hardest part of that. Stay physically active, combining aerobic and resistance work. Sleep enough. Manage chronic stress. Research suggests visceral fat responds to these more readily than subcutaneous fat does.

Two compounds have a mechanism relevant to the fructose route specifically.

Luteolin has been studied for its interaction with fructokinase in preclinical models. That enzyme starts the sequence linking fructose to liver fat. Evidence is preclinical.

Tart cherry anthocyanins have been studied for effects on uric acid and inflammatory markers in small human trials. Evidence for uric acid effects is moderate.

Neither replaces the changes above. Neither has been shown to reduce visceral fat directly in human trials.

At LIV3, we see visceral fat as a signal rather than the root problem. It suggests the liver is handling more fructose than it can process without turning the surplus into fat.

Addressing it means looking at the step that decides what happens to fructose in the first place. That is more useful than focusing on the fat itself.

SugarShield delivers liposomal luteolin alongside tart cherry extract. It is designed to support fructose metabolism at the point where that metabolism begins.

SugarShield is a food supplement, not a medicine. It is not intended to diagnose, treat, cure, or prevent any disease.

MASTER GUIDE: The Complete Science of How Fructose Reshapes Your Metabolism

DE NOVO LIPOGENESIS: How Fructose Becomes Fat in the Liver

INSULIN RESISTANCE: The Fructose, ATP and Uric Acid Pathway Behind Insulin Resistance

ENDOGENOUS FRUCTOSE: Why a Low-Sugar Diet Does Not Always Remove Fructose Exposure

Fox, C. S., Massaro, J. M., Hoffmann, U., Pou, K. M., Maurovich-Horvat, P., Liu, C. Y., Vasan, R. S., Murabito, J. M., Meigs, J. B., Cupples, L. A., D’Agostino, R. B., & O’Donnell, C. J. (2007). “Abdominal visceral and subcutaneous adipose tissue compartments: Association with metabolic risk factors in the Framingham Heart Study.” Circulation, 116(1), 39-48.

Item, F., & Konrad, D. (2012). “Visceral fat and metabolic inflammation: The portal theory revisited.” Obesity Reviews, 13(Suppl 2), 30-39.

Neeland, I. J., Ross, R., Després, J. P., Matsuzawa, Y., Yamashita, S., Shai, I., Seidell, J., Magni, P., Santos, R. D., Arsenault, B., Cuevas, A., Hu, F. B., Griffin, B., Zambon, A., Barter, P., Fruchart, J. C., & Eckel, R. H. (2019). “Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: A position statement.” The Lancet Diabetes & Endocrinology, 7(9), 715-725.

Stanhope, K. L., Schwarz, J. M., Keim, N. L., Griffen, S. C., Bremer, A. A., Graham, J. L., Hatcher, B., Cox, C. L., Dyachenko, A., Zhang, W., McGahan, J. P., Seibert, A., Krauss, R. M., Chiu, S., Schaefer, E. J., Ai, M., Otokozawa, S., Nakajima, K., Nakano, T., & Havel, P. J. (2009). “Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans.” Journal of Clinical Investigation, 119(5), 1322-1334.